The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...
Hosted on MSN19h
Phase III Trials: It’s crunch time for these ASX health stocksSeveral ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...
Inc. (NASDAQ:RCEL), recently acquired 486 shares of the company's common stock. The transaction, dated December 9, 2024, was executed at a price of $13.15 per share, amounting to a total purchase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback